Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02020304 · ClinicalTrials.gov registry record · Phase 2
Combined Spinal-Epidural Temperature and Duration of Action
A Phase 2 study of Pain, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT02020304: Completed Phase 2 study of Pain, sponsored by Wake Forest University Health Sciences.
NCT02020304 is a Phase 2 study of Pain that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 58 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02020304, a Phase 2 study of Pain, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis is that a combined spinal-epidural drug at refrigerated temperature will have a shorter period of pain relief than that maintained at room temperature. The temperature of the dose of medication will be measure with an infrared thermometer immediately prior (within 5 minutes) to administration.
Primary Outcome
length of time in minutes the combined spinal epidural dose duration is calculated from the time of administration until the request is made for additional analgesia (\~1.5-3 hours) post dose. The subjects epidural is then dosed as per standard of care.
Conditions Studied
Interventions
- DRUG combined spinal epidural
Study Locations (1)
North Carolina
- Forsyth Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2013-08-29 |
| Est. Completion | 2014-05-04 |
| Phase | Phase 2 |
What the finished NCT02020304 record still lists
NCT02020304 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 1 intervention - of which combined spinal epidural is the first listed.
NCT02020304 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02020304 about?
NCT02020304 is a clinical study titled "Combined Spinal-Epidural Temperature and Duration of Action". The hypothesis is that a combined spinal-epidural drug at refrigerated temperature will have a shorter period of pain relief than that maintained at room temperature. The temperature of the dose of medication will be measure with an infrared thermometer immediately prior (within 5 minutes) to admini...
What is the current status of trial NCT02020304?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2013-08-29. Estimated completion is 2014-05-04.
What conditions does trial NCT02020304 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT02020304?
The interventions under investigation include: combined spinal epidural (DRUG).
Who is sponsoring clinical trial NCT02020304?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02020304 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02020304's enrollment target sits among peer trials
58 242nd of 374 higher than 132 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Neural Correlates of Hypoalgesia Driven by Observation
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
-
Pain After Buffered Vs Non Buffered Articaine
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI